Dana-Farber Research News 03.15.2026 - Takeaways - MDSpire

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • March 15, 2026

  • 21 min

Share

  • 1

    Dana-Farber's Research News highlights recent publications by faculty, focusing on research from February 16 to 28, 2026.

  • 2

    A study in Blood reveals the role of interferon gamma in mortality linked to adult hemophagocytic lymphohistiocytosis.

  • 3

    Research shows giant DNA viruses possess a functional translation-initiation complex, challenging previous notions about viral protein synthesis.

  • 4

    A clinical trial indicates stereotactic radiation is more effective than whole brain radiation for managing symptoms in patients with multiple brain metastases.

  • 5

    The SONIA trial suggests that earlier administration of CDK4/6 inhibitors may improve outcomes in advanced breast cancer patients.

Original Source(s)

Dana-Farber Research News 03.15.2026

  • March 15, 2026

Related Content

Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min
2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

  • July 2, 2026

  • 1 min
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • by

  • June 24, 2026

  • 4 min